Skip to main content
. 2016 Jun 23;11(6):e0157961. doi: 10.1371/journal.pone.0157961

Fig 3. Summary of Disease Remission and Low Disease Activity Based on DAS28-ESR.

Fig 3

Bars show the percentage of patients who achieved disease remission (DAS28-ESR <2.6; shaded portion of each bar) or low disease activity (DAS28-ESR ≥2.6 to <3.2; non-shaded portion of each bar) by ofatumumab treatment course in OFA110635 (panel A), OFA110634 (panel B) and OFA111752 (panel C).